All In Biotech

Drug Trial Radar · NCT04009681

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

175

Actual

Start

Jun 20, 2019

Primary completion

Dec 2, 2025

Study completion Dec 2, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: * Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs) in Cohorts A, B, C, D, and G, and adverse events (AEs)/serious adverse event (SAE) profile in Cohorts A, B, C, D, E, F, and G) * Define the Maximium Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and as a combination therapy (Cohorts A, B, C, D, and G) * Evaluate preliminary anti-tumor activity of THOR-707 as a single agent by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohort H only) Secondary Objectives: * Evaluate preliminary anti-tumor activity of THOR-707 as a single agent and as a combination therapy by determination of the objective response rate (ORR) defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Cohorts A, B, C, D, E, F, and G) * Determine time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and clinical benefit rate (CBR) of THOR-707 as a single agent and as a combination therapy * Evaluate the safety and tolerability of THOR-707 monotherapy QW/Q2W (AE/serious adverse event \[SAE\] profile) (Cohort H only).

Conditions

  • Metastasis

Interventions

  • THOR-707Drug

    Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration

  • Checkpoint inhibitorDrug

    Pharmaceutical form: solution for IV administration; Route of administration: IV administration

  • anti-EGFR antibodyDrug

    Pharmaceutical form: solution for IV administration; Route of administration: IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Dose-Limiting Toxicities (DLTs)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
  2. Maximum Tolerated Dose (MTD)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
  3. Recommended Phase 2 Dose (RP2D)- Cohorts A, B, C, and DTime frame: Study Day 1 up to Day 29
  4. Number of participants with treatment emergent adverse events, serious adverse events, and laboratory abnormalities - Cohorts A, B, C, D, E, F, and GTime frame: Study Day 1 up to approximately 24 months
  5. Rate of Dose-Limiting Toxicities (DLTs) -Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
  6. Recommended Phase 2 Dose (RP2D) of THOR-707- Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
  7. Maximum Tolerated Dose (MTD)- Cohort GTime frame: Study Day 1 up to Day 42 (6 week-cycle)
  8. Objective Response Rate (ORR) according to RECIST version 1.1 -Cohort HTime frame: Study Day 1 up to approximately 24 months

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site Number-1008

    Scottsdale, Arizona

  • Investigational Site Number-1005

    Denver, Colorado

  • Investigational Site Number-1004

    Sarasota, Florida

  • Investigational Site Number-1003

    Nashville, Tennessee

  • Investigational Site Number-1007

    Dallas, Texas

  • Investigational Site Number-1002

    Houston, Texas

  • Investigational Site Number-1001

    San Antonio, Texas

  • Investigational Site Number-7002

    Buenos Aires, Argentina

  • Investigational Site Number-2004

    New South Whales, Australia

  • Investigational Site Number-2001

    Perth, Australia

  • Investigational Site Number-2002

    Victoria, Australia

  • Investigational Site Number-2003

    Victoria, Australia

  • Investigational Site Number- 6001

    Santiago, Chile

  • Investigational Site Number-6002

    Santiago, Chile

  • Investigational Site Number-4002

    Singapore, Singapore

  • Investigational Site-4001

    Singapore, Singapore

  • Investigational Site Number-5001

    Barcelona, Spain

  • Investigational Site Number-5006

    Barcelona, Spain

  • Investigational Site Number-5007

    Barcelona, Spain

  • Investigational Site Number-5002

    Madrid, Spain

  • Investigational Site Number-5003

    Madrid, Spain

  • Investigational Site Number-5004

    Madrid, Spain

  • Investigational Site Number-5005

    Madrid, Spain

  • Investigational Site Number-5105

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.